Undifferentiated carcinoma of the transverse colon with rhabdoid features that developed during treatment of non-small cell lung carcinoma with pembrolizumab: a case report

Yuya Ashitomi1*, Mitsuhiro Yano1, Michihisa Kono1, Takefumi Suzuki1, Ichiro Kawamura1, Shinji Okazaki1, Yukinori Kamio1, Osamu Hachiya1, Yuka Urano2 and Fuyuhiko Motoi1

Abstract

Background: Undifferentiated carcinoma of the colon is rare, and its prognosis is very poor. We report a case of undifferentiated carcinoma of the colon with rhabdoid features developed during treatment of non-small lung carcinoma (NSCLC) with pembrolizumab.

Case presentation: A 58-year-old man was diagnosed with transverse colon cancer during chemotherapy with pembrolizumab for NSCLC. Laparoscopic right hemicolectomy was performed. The histopathological diagnosis was undifferentiated carcinoma with rhabdoid features and lymph node metastasis. Immunohistochemically, programmed death ligand 1 (PD-L1) showed positivity. The microsatellite instability (MSI) status was low. He continued to receive pembrolizumab for NSCLC, and there have been no signs of colon cancer recurrence and progression of NSCLC for 15 months.

Conclusion: We present the case of an undifferentiated carcinoma of the transverse colon with rhabdoid features. The development of the tumor with the expression of PD-L1 during pembrolizumab might have been associated with the low MSI.

Keywords: Colorectal cancer, Undifferentiated carcinoma, Rhabdoid tumor, Pembrolizumab

Background

Undifferentiated carcinoma with rhabdoid features is rare and confers poor prognosis [1]. These tumors have been reported to occur at several sites, such as the central nervous system, gastrointestinal tract, heart, breast, and urinary tract [2, 3]. Pembrolizumab is an immune checkpoint inhibitor (ICI) that targets programmed death-1 (PD-1) [4]. It is used for the treatment of many types of cancers, including non-small cell lung cancer (NSCLC). We report a case of undifferentiated carcinoma of the transverse colon with rhabdoid features developed during treatment of NSCLC with pembrolizumab.

Case presentation

A 58-year-old man was receiving pembrolizumab as a 1st line treatment for NSCLC (showing differentiation into adenocarcinoma and squamous cell carcinoma) and multiple bone metastases for 9 months. The patient presented with anemia and bloody stools. Colonoscopy revealed a type 3 lesion at the transverse colon, and the
biopsy showed an undifferentiated carcinoma. Computed tomography showed multiple swollen lymph nodes along the superior mesenteric artery. \(^{18}\)F-fluorodeoxyglucose positron emission tomography was performed for disease evaluation, and accumulation was observed in the right colon (maximum standardized uptake value of 22) (Fig. 1). The preoperative diagnosis was \(cT3N1bM0\) stage IIIIB (union for international cancer control (UICC) 8th edition) locally advanced transverse colon cancer. We performed laparoscopic right hemicolectomy with lymphadenectomy. He was discharged on the 10 days after the surgery without postoperative complications. The resected specimen showed a tumor measuring 75 × 46 mm (Fig. 2). Histologically, undifferentiated cancer cells and diffuse invasion of rhabdoid tumors were observed. Immunohistochemically, the tumor cells tested positive for AE1/AE3 and focally positive for CAM5.2 and epithelial membrane antigen. Programmed death-ligand 1 (PD-L1) tested positive (Fig. 3). Synaptophysin, chromogranin A, thyroid transcription factor-1, surfactant protein A, cytokeratin 5/6, p40, S-100P, D2-40, leukocyte common antigen, \(\alpha\)-smooth muscle actin, desmin, calponin, h-caldesmon, cytokeratin 20, and E-cadherin were all tested negative. The microsatellite instability (MSI) status was low. The final diagnosis was undifferentiated carcinoma with rhabdoid features and lymph node metastasis (\(pT3N2aM0\) Stage IIIIB, UICC 8th edition). He continued to be received pembrolizumab for NSCLC. There have been no signs of colon cancer recurrence and progression of NSCLC for 15 months.

**Discussion**

Pembrolizumab is an ICI, a relatively new drug. Pembrolizumab is a humanized monoclonal Immunoglobulin G4 kappa antibody that prevents PD-1 from binding with two ligands: PD-L1 and programmed death ligand 2 \([4]\). Pembrolizumab has shown significant efficacy for PD-L1-positive NSCLC in clinical trials \([5-7]\), and the Food and Drug Administration in USA approved pembrolizumab for the treatment of metastatic NSCLC. Pembrolizumab is now used for not only NSCLC but also for various tumors such as melanoma and MSI-high solid tumors \([4, 8-12]\). In present case, NSCLC with bone metastasis exhibited PD-L1 positivity. The patient received pembrolizumab, and the NSCLC was controlled without disease progression. Unlike other drugs, most adverse events (AEs) of ICIs are thought to be immune-related AEs. ICIs affect immune system, resulting in immune-related AEs such as hypothyroidism, diabetes mellitus, and pneumonitis \([4]\).

Rhabdoid tumors were first reported in young children with renal tumors \([13, 14]\). This tumor was later reported at several sites, such as central nervous system, gastrointestinal tract, heart, breast, and urinary tract \([15]\). Rhabdoid tumors are histologically characterized by the unique morphological features of proliferating rhabdoid cells, which have abnormally located large nuclei, prominent nucleoli, and typical eosinophilic inclusion of aggregated intermediate filament \([3, 13]\). Rhabdoid tumors are classified into two types: composite and pure.

**Fig. 1** Image of the transverse colon cancer. Colonoscopy showed a type 3 tumor with necrotic tissue (a). Contrast-enhanced CT did not indicate colon cancer (b). Positron emission tomography showed an accumulation of \(^{18}\)F-fluorodeoxyglucose in the colon (c).
Both show similar morphologic features and immunohistochemical results [16]. There is no standard therapeutic protocol for these tumors, and previous reports indicate a poor prognosis [17, 18]. Moussaly et al. reported that most patients with colorectal rhabdoid tumors died within 6 months after surgery [19]. However, there were few reports of cases involving long-term survival of more than 1 year [1, 16, 20, 21]. The histogenesis of rhabdoid tumor is uncertain. In present case, the colonic tumor that developed during treatment with pembrolizumab was undifferentiated carcinoma despite PD-L1 positivity. In NSCLC, PD-L1 expression is associated with the response of pembrolizumab [5]. Czink E, et al. reported the MSI-high biliary tract cancer with a lack of expression of PD-L1 may be successfully treated by ICIs [22]. Some reports suggest that there is no association between the treatment effects of anti-PD-1/PD-L1 agents and the value of PD-L1 [23]. The therapeutic

![Figure 2](image_url) Macroscopic findings of the resected specimen. The tumor size was 75 × 46 mm

![Figure 3](image_url) Histological and immunohistochemical studies. Hematoxylin and eosin staining of tumor cells with rhabdoid cells (a, × 40, b × 400). AE1/AE3 positivity (c), CAM 5.2 focally positivity (d), EMA focally positivity (e), Programmed death-ligand 1 positivity (f)
effect of pembrolizumab for the colon cancer was insufficient because the tumor had been progressed during the treatment in presented case. However, it could be speculated that pembrolizumab has prevented distant recurrence of this highly malignant tumor for more than 1 year. Further investigations would provide insight into the clinicopathological feature of this highly malignant tumor and its association with the actions of ICIs. To the best of our knowledge, there have been no reports of carcinoma that have developed during treatment with ICIs.

**Conclusion**

We present a 58-year-old man who was found to have an undifferentiated carcinoma of the transverse colon with rhabdoid features. The development of this PD-L1 expressed tumor during pembrolizumab treatment might have been associated with the low tumor mutational burden indicated by low MSI.

**Abbreviations**

ICIs: Immune checkpoint inhibitors; PD-1: Programmed death-1; NSCLC: Non-small cell lung cancer; UICC: Union for international cancer control; PD-L1: Programmed death-ligand 1; MSI: Microsatellite instability; AEs: Adverse events

**Acknowledgements**

Not applicable.

**Authors’ contributions**

YA described and designed this manuscript. MY, SO, and IK were the surgeon who did the operation and contributed to the critical revision of this manuscript. YU was the pathologist who did the diagnosis. OH and FM contributed to the critical revision and final approval of this manuscript.

**Funding**

No funding.

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

Institutional ethics committee approval was taken for the publication (no.2 019-5-9).

**Consent for publication**

Written informed consent was obtained from the patients for publication of this case report and accompanying images.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. First Department of Surgery, Yamagata University Faculty of Medicine, 2-2-2, Iida-Nishi, Yamagata City, Yamagata 990-9585, Japan. 2. Department of Pathological Diagnostics, Yamagata University Faculty of Medicine, 2-2-2, Iida-Nishi, Yamagata City, Yamagata 990-9585, Japan.

**Received:** 22 June 2020  **Accepted:** 27 July 2020  **Published online:** 03 August 2020

**References**

1. D’Amico F, Bertacco A, Cesari M, Moscoli C, Caturegli G, Gondolesi G, et al. Extraordinary disease-free survival in a rare malignant extracranial rhabdoid tumor: a case report and review of the literature. J Med Case Rep. 2018;12:39.

2. Parham DM, Weeks DA, Beckwith JB. The clinicopathologic spectrum of putative extrarenal rhabdoid tumors. An analysis of 42 cases studied with immunohistochemistry or electron microscopy. Am J Surg Pathol. 1994;18:1010–29.

3. Wick MR, Ritter JH, Denhner LP. Malignant rhabdoid tumors: a clinicopathologic review and conceptual discussion. Semin Diagn Pathol. 1995;12:233–48.

4. Kwok G, You TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016;12:2777–89.

5. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Córdoba T, Fulpò A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375:1823–33.

6. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cheng BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819–30.

7. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50.

8. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372:2521–32.

9. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390:1853–62.

10. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018;378:789–901.

11. Le DT, Kim TW, van Custem E, Geva R, Jäger D, Hara H, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38:1–9.

12. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Dekord JP, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38:1–10.

13. Haas JE, Palmer NF, Weinberg AG, Beckwith JB. Ultrastructure of malignant rhabdoid tumor of the kidney. A distinctive renal tumor of children. Hum Pathol. 1981;12:646–57.

14. Palmer NF, Sutow W. Clinical aspects of the rhabdoid tumor of the kidney: a report of the National Wilms’ Tumor Study Group. Med Pediatr Oncol. 1983;11:242–5.

15. Nakamura I, Nakano K, Nakayama K, Ishi Y, Ohta K, Takahashi M, et al. Malignant rhabdoid tumor of the colon: report of a case. Surg Today. 1999;29:1083–7.

16. Lee SH, Seol H, Kim WY, Lim SD, Kim WS, Hwang TS, et al. Rhabdoid colorectal carcinomas reports of two cases. Korean J Pathol. 2013;47:372–7.

17. Salamanca J, Nevado M, Martínez-González MA, Pérez-Estepa G, Pinedo F. Undifferentiated carcinoma of the jejunum with extensive rhabdoid features. Case report and review of the literature. APMS. 2008;116:941–6.

18. Cho JJ, Kim SS, Min YD, Noh MW, Hong R. Poorly differentiated cecal adenocarcinoma showing prominent rhabdoid feature combined with appendiceal mucinous cystadenoma: A case report and review of the literature. Oncol Lett. 2015;9:1527–30.

19. Mosayyel E, Atallah JP. A rare case of undifferentiated carcinoma of the colon with rhabdoid features: a case report and review of the literature. Case Rep Oncol Med. 2015. https://doi.org/10.1155/2015/531348.

20. Marcus VA, Vioria J, Owen D, Tsao MS. Malignant rhabdoid tumor of the colon. Report of a case with molecular analysis. Dis Colon Rectum. 1996;39:1322–3.

21. Han SL, Li JL, Liu Z, Cheng J, Guo SC, Wu SL. Malignant rhabdoid tumor of rectum: report of a case. Tech Coloproctol. 2010;14:199–200.

22. Cizik E, Koo R, Goaepert B, Froshing S, Lihing S, Weber TF, et al. Successful checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. Cold Spring Harb Mol Case Stud. 2017;3:a001974.

23. Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, et al. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 2017;112:200–15.